ENVISAGENICS
Envisagenics focus on the discovery of RNA therapeutics. Their mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Their breakthrough technolo... gy, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug targets, and develop RNA therapeutics through partnerships and collaborations with Biopharma. Their in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs. Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory.
ENVISAGENICS
Industry:
Artificial Intelligence Bioinformatics Biotechnology Machine Learning Therapeutics
Founded:
2014-04-22
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.envisagenics.com
Total Employee:
11+
Status:
Active
Contact:
(516)847-5485
Email Addresses:
[email protected]
Total Funding:
27.06 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins
Current Advisors List
Current Employees Featured
Founder
Investors List
National Cancer Institute
National Cancer Institute investment in Grant - Envisagenics
M12 - Microsoft's Venture Fund
M12 - Microsoft's Venture Fund investment in Series A - Envisagenics
New York Ventures
New York Ventures investment in Series A - Envisagenics
Madrona Venture Group
Madrona Venture Group investment in Series A - Envisagenics
Third Kind Venture Capital
Third Kind Venture Capital investment in Series A - Envisagenics
Dynamk Capital
Dynamk Capital investment in Series A - Envisagenics
Red Cell Partners
Red Cell Partners investment in Series A - Envisagenics
National Cancer Institute
National Cancer Institute investment in Grant - Envisagenics
National Institutes of Health
National Institutes of Health investment in Grant - Envisagenics
Madrona Venture Group
Madrona Venture Group investment in Seed Round - Envisagenics
Official Site Inspections
http://www.envisagenics.com
- Host name: 104.21.52.45
- IP address: 104.21.52.45
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Envisagenics"
About Us - ENVISAGENICS
Envisagenics is a spinout of the world-renowned Cold Spring Harbor Laboratory (CSHL) from the laboratory of Dr. Adrian R. Krainer, a leading expert in the field of splicing. The Krainer …See details»
Envisagenics - Crunchbase Company Profile & Funding
Organization. Envisagenics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Read …See details»
Envisagenics - LinkedIn
Envisagenics is honored to have participated in BIO-Europe 2024 in Stockholm, an event hosted by EBD Group and the Biotechnology Innovation Organization that brings together leaders from across ...See details»
Envisagenics Company Profile 2024: Valuation, Funding …
Envisagenics General Information Description. Developer of a bioinformatics platform intended to accelerate the development of novel therapeutics. The company's platform incorporates advanced artificial intelligence and machine …See details»
Envisagenics Raises Series B to Fuel AI-Enabled Novel Therapeutic ...
Jun 5, 2024 Founded in 2014 as a spin-out from Cold Spring Harbor Laboratory, Envisagenics is a woman- and minority-led organization, with several grants from esteemed institutions like the …See details»
Envisagenics Validates AI/ML Approach for RNA Target …
Apr 25, 2024 About Envisagenics. ... Founded in 2014 as a spin-out from Cold Spring Harbor Laboratory, we take pride in being a woman- and minority-led organization, with several grants from esteemed ...See details»
Envisagenics - Funding, Financials, Valuation
Envisagenics is funded by 18 investors. Third Kind Venture Capital and Empire State Development are the most recent investors. Envisagenics has a post-money valuation in the range of $1M to $10M as of Nov 28, 2017, according …See details»
Envisagenics Raises Series B to Fuel AI-Enabled Novel ... - BioSpace
Jun 5, 2024 Envisagenics collaborates closely with biopharmaceutical companies and academic institutions to elevate their drug discovery capabilities and has partnered with the Lung Cancer …See details»
Envisagenics Raises Series B to Fuel AI-Enabled Novel Therapeutic ...
Jun 5, 2024 Envisagenics, an AI-driven revenue generating biotechnology company focused on discovery and development of novel RNA splicing therapeutics, today announced a Series B …See details»
Envisagenics Raises Series A Financing to Scale Its AI …
NEW YORK, NY, September 29, 2021 – Envisagenics, an Artificial Intelligence-driven biotechnology company focused on the discovery and development of novel RNA splicing therapeutics, secured Series A financing to scale its drug …See details»
Envisagenics - Contacts, Employees, Board Members, Advisors
Organization. Envisagenics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. Number of Board …See details»
Envisagenics - VentureRadar
Envisagenics focuses on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA …See details»
Envisagenics Raises Series A Financing to Scale Its AI-powered …
Sep 29, 2021 Envisagenics a minority- and woman-led company that partners with biopharmaceutical companies and academic institutions to advance their drug discovery …See details»
Envisagenics Validates AI/ML Approach for RNA Target …
Apr 25, 2024 Envisagenics collaborates closely with biopharmaceutical companies and academic institutions to elevate their drug discovery capabilities and have previously partnered …See details»
Envisagenics Raises Series B to Fuel AI-Enabled Novel Therapeutic ...
Envisagenics is an AI-driven biotechnology company harnessing the therapeutic potential of RNA splicing. Over 95% of human genes undergo alternative splicing, a process generating multiple …See details»
Envisagenics is Awarded Another SBIR Grant From the National …
Aug 2, 2022 Envisagenics is a spin-out of Cold Spring Harbor Laboratory and a proud woman- and minority-led recipient of several grants from the National Institute of General Medical …See details»
Envisagenics : Raises Series A Financing to Scale Its AI-powered …
NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Envisagenics, an Artificial Intelligence-driven biotechnology company focused on the discovery and development of novel RNA splicing …See details»
Our Science - ENVISAGENICS
Envisagenics’ machine learning module for the identification of tumor-specific RNA splicing-derived neoepitopes SPINRAZA ® Led by Dr. Adrian Krainer, Envisagenics’ founding scientific …See details»
Envisagenics Validates AI/ML Approach for RNA Target …
Apr 25, 2024 Envisagenics, an AI-driven biotechnology company, today announced the publication in the journal Molecular Systems Biology of study results evaluating the company's …See details»